Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROR1 | Q01973 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6433538 | 0.82 | ROR1 (0.34) | ROR1PREPCA12CA1CA9 | |
| SCHEMBL6434856 | 0.79 | ROR1 (0.36) | ROR1CYP19A1MRGPRX4 | |
| SCHEMBL6485171 | 0.79 | ROR1 (0.33) | ROR1PREPCYP19A1 | |
| SCHEMBL6434923 | 0.74 | ROR1 (0.36) | ROR1CYP19A1KDM4EALDH1A1 | |
| SCHEMBL613626 | 0.73 | ROR1 (0.36) | ROR1CYP19A1KDM4EALDH1A1 | |
| SCHEMBL6433135 | 0.73 | PDE10A (0.39) | ROR1CYP19A1ALDH1A1 | |
| SCHEMBL1516074 | 0.73 | PREP (0.40) | PREPCA12CA1CA9MCHR1 | |
| SCHEMBL6433944 | 0.72 | CA12 (0.39) | PREPCA12CA1CA9 | |
| SCHEMBL5360778 | 0.72 | CA12 (0.39) | PREPCA12CA1CA9 | |
| SCHEMBL5363897 | 0.72 | CA12 (0.39) | PREPCA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1165495-B1 | RESORCINOL DERIVATIVES | PFIZER (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209949-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | ROR1 472/4885PREP 1298/4885CA12 4452/4885 |
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | ROR1 472/4885PREP 1298/4885CA12 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.